Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
betulaceae allergenic extract
- Development stage
- Unknown
- Lead developer
- Lofarma
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual, Percutaneous
01
Overview
Betulaceae allergenic extract is a biological allergen extract developed by LOFARMA S.p.A. for use in allergen-specific immunotherapy (ASIT). Derived from the pollen of plants in the Betulaceae family, particularly *Betula verrucosa* (birch), the extract is intended for the treatment of respiratory allergies, including allergic rhinitis and allergic asthma, in sensitized patients. It functions as a therapeutic vaccine that modulates the IgE-mediated immune response to birch pollen allergens, with the major target being the Bet v 1 allergen. The extract has been evaluated in Phase 2 clinical trials for biological standardization to determine its potency in histamine equivalent prick (HEP) units and to establish reference preparations for clinical use.
- Brand names
- ItulazaxStaloralAlutard SQ
- Other names
- birch pollen allergenic extractBetula verrucosa allergenic extractbirch pollen extract
02
Targets
A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)
Beyond the preview
Go deeper on betulaceae allergenic extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on betulaceae allergenic extract.